Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
dc.contributor.author | van As, Nicholas | |
dc.contributor.author | Griffin, Clare | |
dc.contributor.author | Tree, Alison | |
dc.contributor.author | Patel, Jaymini | |
dc.contributor.author | Ostler, Peter | |
dc.contributor.author | van der Voet, Hans | |
dc.contributor.author | Loblaw, Andrew | |
dc.contributor.author | Chu, William | |
dc.contributor.author | Ford, Daniel | |
dc.contributor.author | Tolan, Shaun | |
dc.contributor.author | Jain, Suneil | |
dc.contributor.author | Camilleri, Philip | |
dc.contributor.author | Kancherla, Kiran | |
dc.contributor.author | Frew, John | |
dc.contributor.author | Chan, Andrew | |
dc.contributor.author | Naismith, Olivia | |
dc.contributor.author | Armstrong, John | |
dc.contributor.author | Staffurth, John | |
dc.contributor.author | Martin, Alexander | |
dc.contributor.author | Dayes, Ian | |
dc.contributor.author | Wells, Paula | |
dc.contributor.author | Price, Derek | |
dc.contributor.author | Williamson, Emily | |
dc.contributor.author | Pugh, Julia | |
dc.contributor.author | Manning, Georgina | |
dc.contributor.author | Brown, Stephanie | |
dc.contributor.author | Burnett, Stephanie | |
dc.contributor.author | Hall, Emma | |
dc.date.accessioned | 2024-11-11T14:16:06Z | |
dc.date.available | 2024-11-11T14:16:06Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | N. van As, C. Griffin, A. Tree, J. Patel, P. Ostler, H. van der Voet, A. Loblaw, W. Chu, D. Ford, S. Tolan, S. Jain, P. Camilleri, K. Kancherla, J. Frew, A. Chan, O. Naismith, J. Armstrong, J. Staffurth, A. Martin, I. Dayes, P. Wells, D. Price, E. Williamson, J. Pugh, G. Manning, S. Brown, S. Burnett, and E. Hall | en_US |
dc.identifier.eissn | 1533-4406 | |
dc.identifier.doi | 10.1056/NEJMoa2403365 | |
dc.identifier.pmid | 39413377 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14200/6469 | |
dc.description.abstract | Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Massachusetts Medical Society | en_US |
dc.relation.url | DOI: 10.1056/NEJMoa2403365 | en_US |
dc.rights | Copyright © 2024 Massachusetts Medical Society. | |
dc.title | Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. | en_US |
dc.type | Article | en_US |
dc.type | Other | en_US |
dc.source.journaltitle | The New England Journal of Medicine | en_US |
dc.source.volume | 391 | |
dc.source.issue | 15 | |
dc.source.beginpage | 1413 | |
dc.source.endpage | 1425 | |
dc.source.country | United Kingdom | |
dc.source.country | United Kingdom | |
dc.source.country | United States | |
rioxxterms.version | AO | en_US |
dc.contributor.trustauthor | Ford, Daniel | |
dc.contributor.department | Oncology | |
dc.contributor.role | Medical and Dental | en_US |
dc.date.accepted | 2024 | |
dc.identifier.journal | The New England journal of medicine | |
oa.grant.openaccess | yes | en_US |